Hence we infer that early colorectal carcinoma is an important model for targeted therapy with antiangiogenic factors for VEGF. The decreased expression of VEGF in higher grades and stages of adenocarcinomas suggests that it has a reduced role in tumor progression. The gene discussed is VEGFA; the disease is adenocarcinoma.